Long-term follow-up after prior EB-101 treatment for RDEB
Part of Genetic & congenital, Skin clinical trials.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian, if you’re under 18) can give consent/assent
- You were previously treated with EB-101 in an earlier study
- You are able and willing to follow the study plan and instructions
- The study team agrees you can safely take part based on whether you can follow the protocol
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
This study follows patients who have already received a gene therapy treatment called prademagene zamikeracel for a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). The goal is to track long-term safety and health outcomes after treatment.
This study looks at the medical features and needs of people who have recessive dystrophic epidermolysis bullosa (RDEB). It may help doctors better understand the condition and plan better care.
This study checks how adults are doing long-term after receiving an HIV treatment called EBT-101 in an earlier study. It helps researchers understand safety and longer-term effects over time.
This trial tests a gene therapy called BVEC to see if it can prevent squamous cell carcinoma (a type of skin cancer) from coming back in people with a severe form of epidermolysis bullosa (fragile skin). It is for adults who have had a confirmed SCC and are willing to use the gene therapy.
This study looks at the immune system in people with recessive dystrophic epidermolysis bullosa (RDEB) and tests how placental stem cells affect immune cells in the lab. It aims to understand the disease better and explore potential treatments.
Hear when a new RDEB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.